More importantly, it can also inhibit the growth of lymphoma and leukemia cells [96], overcoming the limitations of the BTK inhibitor, ibrutinib, in the treatment of non-mutant MyD88 lymphoma and providing new treatment ideas for WT MyD88 lymphoma. This evidence concerns the gene BTK and lymphoma.